Psma Targeted Therapy: How It Works, Results and What to Expect

PSMA targeted therapy is a precision cancer treatment used mainly for selected people with advanced prostate cancer. It uses a radioactive medicine that attaches to prostate-specific membrane antigen (PSMA) on cancer cells, helping deliver radiation directly to sites of disease while limiting exposure to most healthy tissues.

Overview: what is PSMA targeted therapy?

PSMA targeted therapy is a form of radioligand therapy for prostate cancer. It combines a molecule designed to find prostate-specific membrane antigen (PSMA) with a radioactive particle. After being given into a vein, the medicine circulates through the body, binds to PSMA-expressing cancer cells and releases radiation over a very short distance.

Many prostate cancer cells, particularly in advanced disease, have higher amounts of PSMA on their surface than most normal tissues. This makes PSMA a useful target for imaging and treatment. The best-known treatment in this group uses lutetium-177 attached to a PSMA-binding ligand; it is often described as Lu-177 PSMA therapy.

PSMA targeted therapy is not usually the first treatment for localized prostate cancer. It is primarily used for selected people with prostate cancer that has spread and is no longer adequately controlled by hormone-lowering treatment. A multidisciplinary review helps determine whether it fits alongside, before or after other treatments such as chemotherapy, androgen-receptor-targeted medicines or focused radiation.

How PSMA targeted therapy works

PSMA is a protein found on the surface of many prostate cancer cells. Before treatment, clinicians commonly use a PSMA PET scan to map where PSMA-positive disease is located. The scan also helps show whether the cancer is likely to take up enough of the treatment medicine.

During therapy, the PSMA-binding part of the medicine acts as a guide. It attaches to PSMA-positive cancer cells, and the radioactive component releases beta radiation that damages cancer-cell DNA. Cells that cannot repair this damage may stop dividing or die. Nearby healthy tissue receives much less radiation than the targeted cancer deposit, although some normal structures, including salivary glands and kidneys, can also take up small amounts.

Because metastatic prostate cancer can behave differently from one person to another, scans are interpreted together with medical history, previous treatments, PSA trends, symptoms, blood counts and kidney function. PSMA uptake alone does not determine whether treatment will be beneficial.

Who may be a candidate for treatment?

PSMA targeted therapy may be considered for people with metastatic castration-resistant prostate cancer. This means the cancer has spread beyond the prostate and has continued to grow despite treatment intended to keep testosterone at very low levels. Eligibility depends on local regulatory approvals, treatment availability and the individual clinical situation.

A specialist team commonly considers whether PSMA-positive disease is visible on PET imaging, whether there are cancer sites with little or no PSMA uptake, which treatments have already been used, overall health, symptoms, bone marrow reserve and kidney function. Blood tests are important because treatment can temporarily lower blood cell counts.

Some people may not be suitable if their cancer has insufficient PSMA expression, if there is extensive PSMA-negative disease, or if medical issues make the potential risks too high. Alternative or complementary approaches may include systemic medicines, chemotherapy, external-beam radiation for painful sites, supportive care and other individualized options for prostate cancer.

• PSMA PET imaging helps assess target expression and disease distribution.
• Recent and current prostate cancer treatments are reviewed carefully.
• Kidney function, liver function and blood counts help guide safety decisions.
• Fertility, family-planning concerns and radiation-safety arrangements should be discussed before treatment.

What happens during the procedure and recovery?

Before each treatment cycle, the care team reviews symptoms, medications and laboratory results. Patients may receive guidance about drinking fluids, emptying the bladder regularly and following radiation-safety instructions. The radioactive medicine is generally administered through an intravenous line in a nuclear medicine department, often as an outpatient procedure, although monitoring arrangements vary by center and country.

The infusion itself is typically brief, followed by observation for any immediate concerns. Most people do not feel the radiation working. The treatment course commonly involves several cycles separated by weeks, allowing the team to assess tolerance and response between doses. PSA measurements, blood tests and periodic imaging may be used, but PSA changes should always be interpreted in context.

After treatment, small amounts of radioactivity leave the body mainly in urine. Patients receive individualized instructions about hydration, toileting, hand hygiene, laundry and close contact with others for a limited period. Recommendations are especially important around children and pregnant people, and they differ according to the medicine used and local radiation regulations.

Many people return to routine light activities within a day or two, depending on fatigue and their underlying cancer symptoms. Follow-up is essential because the effects on cancer and blood counts can develop over weeks. PSMA targeted therapy should be coordinated by experienced oncology and nuclear medicine teams.

Benefits, risks and side effects

The potential goal of PSMA targeted therapy is to control PSMA-positive metastatic cancer, reduce symptoms and delay further progression. In clinical studies of appropriately selected patients with advanced prostate cancer, treatment has improved outcomes compared with some standard-care approaches. However, it does not cure metastatic castration-resistant prostate cancer, and the length and degree of benefit vary substantially.

Common side effects can include tiredness, dry mouth, altered taste, nausea, reduced appetite and temporary changes in blood counts. Low red blood cells may contribute to fatigue or breathlessness; low white blood cells can increase infection risk; and low platelets can increase bruising or bleeding. People with widespread bone involvement may be more vulnerable to bone marrow suppression.

Less common but important concerns include kidney effects and significant blood-count reductions. The care team monitors these risks with regular tests and may adjust timing or discontinue treatment if needed. Contact the treatment team promptly for fever, unusual bleeding, severe weakness, worsening shortness of breath, inability to drink fluids or a new concerning symptom.

Supportive care remains an important part of treatment. It may include pain management, nutrition support, treatment of anemia, exercise or rehabilitation adapted to energy levels, and emotional support for patients and families.

What is the success rate of targeted therapy?

There is no single success rate for targeted therapy because the term covers many medicines, cancer types and treatment goals. For PSMA targeted therapy, response may be measured in several ways: a falling PSA level, tumor shrinkage or stabilization on imaging, improvement in pain or other symptoms, longer time before progression, and overall survival. These outcomes do not always occur together.

In selected people with PSMA-positive metastatic castration-resistant prostate cancer, clinical trials have shown that lutetium-177 PSMA therapy can improve disease-control outcomes compared with certain standard-care options. Yet not every person responds, and a PSA decline alone cannot predict the full benefit for an individual.

A person’s likely outcome depends on PSMA PET findings, the amount and location of cancer, prior therapies, general health, blood counts and tumor biology. The oncology team can explain which treatment goals are realistic and how response will be assessed over time.

How many prostate cancers are PSMA positive?

Most prostate cancers express some PSMA, but the amount can vary widely between tumors and even among different cancer deposits in the same person. PSMA expression tends to be more pronounced in many advanced prostate cancers, which is why PSMA PET imaging and PSMA-targeted treatment are particularly useful in that setting.

It is not accurate to assume that every prostate cancer is sufficiently PSMA positive for radioligand therapy. A PSMA PET scan is used to identify whether lesions show adequate uptake and whether there are important areas of disease that may not be targeted well by the treatment.

PSMA is also not exclusive to prostate cancer and can be present at low levels in certain normal tissues. For this reason, scan interpretation and treatment planning require expertise in nuclear medicine, radiology and oncology.

What is the most successful treatment for prostate cancer?

There is no one most successful treatment for every prostate cancer. The best approach depends on whether the cancer is localized, locally advanced, recurrent or metastatic, as well as its grade, PSA level, imaging results, genetic features, symptoms, age, general health and personal priorities.

For localized disease, active surveillance, surgery, radiation therapy and, in selected cases, focal treatment may be appropriate. For advanced disease, treatment commonly involves hormone therapy and may include chemotherapy, androgen-receptor-targeted medicines, radiation, immunotherapy or radioligand therapy. Each option has a different purpose and side-effect profile.

PSMA targeted therapy is a valuable option for some people with advanced PSMA-positive cancer, but it does not replace treatments that are more suitable at earlier stages. Shared decision-making with a urologist, medical oncologist, radiation oncologist and nuclear medicine specialist helps align treatment with the individual situation.

What is the 2 week rule for prostate cancer?

The “2 week rule” is not a universal medical rule for prostate cancer treatment. In some healthcare systems, it refers to an urgent referral pathway intended to help people with symptoms or test results that could indicate cancer see a specialist promptly, often within two weeks. It does not mean that every prostate cancer must be treated within two weeks.

Most prostate cancers develop over years, and a short period for appropriate testing, imaging, pathology review and discussion of options is often medically reasonable. However, suspected aggressive or advanced disease, severe bone pain, spinal symptoms, urinary obstruction, kidney problems or rapidly worsening illness may require faster assessment.

Anyone who has been referred under an urgent pathway should attend appointments promptly and share any new symptoms with the care team. The doctor can explain the urgency in the context of the individual test findings and overall health.

When to seek medical care

People receiving PSMA targeted therapy should contact their clinical team without delay if they develop a fever, signs of infection, unexpected bruising or bleeding, severe dizziness, worsening shortness of breath, chest pain, confusion, persistent vomiting or marked reduction in urine output. These symptoms may have several causes, but they need timely assessment during cancer treatment.

Urgent medical evaluation is also important for new severe back or neck pain, leg weakness, numbness around the groin, loss of bladder or bowel control, or sudden inability to pass urine. In someone with prostate cancer, these symptoms can rarely indicate spinal cord compression or urinary obstruction and should not wait for a routine appointment.

For non-urgent questions about fatigue, dry mouth, appetite changes or practical radiation-safety measures, patients should contact the treatment center. Acibadem International’s multidisciplinary specialists and JCI-accredited hospitals support diagnosis and treatment planning for international patients with advanced prostate cancer.

Frequently asked questions

Is PSMA targeted therapy the same as chemotherapy?

No. PSMA targeted therapy is a radioligand treatment that delivers radiation to cells expressing PSMA, whereas chemotherapy uses medicines that affect rapidly dividing cells more broadly. Both may be used at different points in the care of advanced prostate cancer, depending on the person's treatment history and clinical needs.

How long does PSMA targeted therapy take?

The intravenous administration is usually relatively short, but preparation, monitoring and radiation-safety arrangements can make the visit longer. Treatment is commonly delivered in several cycles separated by weeks, with blood tests and clinical reviews between cycles.

Will PSMA targeted therapy cure metastatic prostate cancer?

PSMA targeted therapy is not generally considered curative for metastatic castration-resistant prostate cancer. Its goals may include slowing cancer growth, relieving symptoms and helping people live longer, depending on individual circumstances.

Do all patients need a PSMA PET scan before treatment?

A PSMA PET scan is commonly used before PSMA radioligand therapy to confirm that the cancer has sufficient PSMA uptake. The scan also helps identify disease that may not be well targeted, which is important for safe and effective treatment planning.

Can PSA rise after PSMA targeted therapy?

PSA levels can fluctuate, particularly early in treatment, and should not be interpreted in isolation. The care team considers PSA together with symptoms, blood tests and imaging before deciding whether treatment is working.

What should patients do after a PSMA treatment session?

Patients should follow the personalized radiation-safety advice provided by their nuclear medicine team, including guidance on fluids, hygiene, toilet use and close contact with others. They should also attend scheduled blood tests and report concerning symptoms promptly.

References

• National Cancer Institute
• European Association of Urology
• American Society of Clinical Oncology
• Society of Nuclear Medicine and Molecular Imaging
• European Medicines Agency

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.